IP Library Granted Patent US 10,329,302
Granted Patent B2
US 10,329,302 · App. 15/862,691 · Granted Jun 25, 2019

Bicyclic-fused heteroaryl or aryl compounds

Inventors: John David Trzupek (Arlington, MA); Katherine Lin Lee (West Newton, MA); Mark Edward Bunnage (Concord, MA); Seungil Han (Mystic, CT); David Hepworth (Concord, MA); Frank Eldridge Lovering (Acton, MA); John Paul Mathias (Concord, MA); Nikolaos Papaioannou (Newton, MA); Betsy Susan Pierce (East Lyme, CT); Joseph Walter Strohbach (Wentzville, MO); Stephen Wayne Wright (Old Lyme, CT); Christoph Wolfgang Zapf (Marlborough, MA); Lori Krim Gavrin (Villanova, PA); Arthur Lee (Littleton, MA); David Randolph Anderson (Salem, CT); Kevin Joseph Curran (Somerset, NJ); Christoph Martin Dehnhardt (Burnaby, CA); Eddine Saiah (Brookline, MA); Joel Adam Goldberg (New Orleans, LA); Xiaolun Wang (San Diego, CA); Horng-Chih Huang (Chesterfield, MO); Richard Vargas (Bedford, MA); Michael Dennis Lowe (White Plains, NY); Akshay Patny (Waltham, MA)
Assignee: Pfizer Inc.
C07D491/056A61K31/40A61K31/4015A61K31/47A61K31/4709A61K31/4725A61K31/517A61K31/5377A61K31/541A61K45/06C07C69/94C07D207/08C07D207/26C07D207/267C07D207/273C07D209/52C07D215/48C07D217/02C07D217/22C07D217/24C07D239/86C07D239/88C07D263/24C07D401/12C07D401/14C07D403/12C07D405/12C07D405/14C07D407/14C07D413/12C07D417/12C07D487/04C07D498/04C07F7/1804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,302
App. No.
15/862,691
Granted
Jun 25, 2019
Kind
B2
Abstract

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Claims (2)

1. A method of treating rheumatoid arthritis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof.

2. A method of treating rheumatoid arthritis in a patient comprising administering to the patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient, or diluent.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (4)
Continuation 15232892 · Aug 10, 2016
Continuation 14678114 · Apr 3, 2015
Provisional Application 61975473 · Apr 4, 2014
Related Publication 20180127432A1 · May 10, 2018
Cited By (2)
US 12,202,836 US 12,247,071